Join us in exploring a new era in cellular therapy

At Rubius Therapeutics, our vision is to bring potentially life-changing cellular therapies to people living with cancer. We call these potential medicines Red Cell Therapeutics™.

Learn About
Red Cell Therapeutics™
Find
a Clinical Trial

Open Clinical Studies

CANCER

Solid Tumors

Rubius Therapeutics is enrolling adults with relapsed/refractory or locally advanced solid tumor cancers into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. Refractory refers to patients who have received treatment, but the disease does not go into remission. Some patients experience remission and then a return of the disease, which is referred to as relapsed.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL


Acute Myeloid Leukemia

Rubius Therapeutics is enrolling adults with relapsed acute myeloid leukemia (AML) or refractory AML into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. Some patients experience remission and then a return of the disease, which is referred to as relapsed. Refractory AML occurs when patients have received approximately two rounds of chemotherapy, but the disease does not go into remission.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL


Thank you

We will contact you about your submission